Shaw A - Search Results

1

Neurotensin agonists: potential in the treatment of schizophrenia.

Boules M, Shaw A, Fredrickson P, Richelson E. Boules M, et al. Among authors: shaw a. CNS Drugs. 2007;21(1):13-23. doi: 10.2165/00023210-200721010-00002. CNS Drugs. 2007. PMID: 17190526 Review.

2

The neurotensin receptor agonist NT69L suppresses sucrose-reinforced operant behavior in the rat.

Boules M, Iversen I, Oliveros A, Shaw A, Williams K, Robinson J, Fredrickson P, Richelson E. Boules M, et al. Among authors: shaw a. Brain Res. 2007 Jan 5;1127(1):90-8. doi: 10.1016/j.brainres.2006.10.025. Epub 2006 Nov 17. Brain Res. 2007. PMID: 17113052

3

A neurotensin analog, NT69L, attenuates intravenous nicotine self-administration in rats.

Boules M, Oliveros A, Liang Y, Williams K, Shaw A, Robinson J, Fredrickson P, Richelson E. Boules M, et al. Among authors: shaw a. Neuropeptides. 2011 Feb;45(1):9-16. doi: 10.1016/j.npep.2010.09.003. Epub 2010 Nov 2. Neuropeptides. 2011. PMID: 21047685

4

Effect of a novel neurotensin analog, NT69L, on nicotine-induced alterations in monoamine levels in rat brain.

Liang Y, Boules M, Shaw AM, Williams K, Fredrickson P, Richelson E. Liang Y, et al. Brain Res. 2008 Sep 22;1231:6-15. doi: 10.1016/j.brainres.2008.07.037. Epub 2008 Jul 19. Brain Res. 2008. PMID: 18687313

5

NT69L, a novel analgesic, shows synergy with morphine.

Boules M, Shaw A, Liang Y, Barbut D, Richelson E. Boules M, et al. Among authors: shaw a. Brain Res. 2009 Oct 19;1294:22-8. doi: 10.1016/j.brainres.2009.07.086. Epub 2009 Aug 3. Brain Res. 2009. PMID: 19651107

6

Paliperidone as a mood stabilizer: a pre-frontal cortex synaptoneurosomal proteomics comparison with lithium and valproic acid after chronic treatment reveals similarities in protein expression.

Corena-McLeod Mdel P, Oliveros A, Charlesworth C, Madden B, Liang YQ, Boules M, Shaw A, Williams K, Richelson E. Corena-McLeod Mdel P, et al. Among authors: shaw a. Brain Res. 2008 Oct 3;1233:8-19. doi: 10.1016/j.brainres.2008.07.021. Epub 2008 Jul 15. Brain Res. 2008. PMID: 18657526

7

Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050.

Shaw AM, Boules M, Zhang Y, Williams K, Robinson J, Carlier PR, Richelson E. Shaw AM, et al. Eur J Pharmacol. 2007 Jan 19;555(1):30-6. doi: 10.1016/j.ejphar.2006.10.004. Epub 2006 Oct 17. Eur J Pharmacol. 2007. PMID: 17109850

8

Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS).

Liang Y, Shaw AM, Boules M, Briody S, Robinson J, Oliveros A, Blazar E, Williams K, Zhang Y, Carlier PR, Richelson E. Liang Y, et al. Among authors: shaw am. J Pharmacol Exp Ther. 2008 Nov;327(2):573-83. doi: 10.1124/jpet.108.143610. Epub 2008 Aug 8. J Pharmacol Exp Ther. 2008. PMID: 18689611

9

Joint ABS-UKCGG-CanGene-CanVar consensus regarding the use of CanRisk in clinical practice.

Tsoulaki O, Tischkowitz M, Antoniou AC, Musgrave H, Rea G, Gandhi A, Cox K, Irvine T, Holcombe S, Eccles D, Turnbull C, Cutress R; Meeting Attendees; Archer S, Hanson H. Tsoulaki O, et al. Br J Cancer. 2024 Jun 4. doi: 10.1038/s41416-024-02733-4. Online ahead of print. Br J Cancer. 2024. PMID: 38834743 Review.

10

Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.

Solomon BJ, Liu G, Felip E, Mok TSK, Soo RA, Mazieres J, Shaw AT, de Marinis F, Goto Y, Wu YL, Kim DW, Martini JF, Messina R, Paolini J, Polli A, Thomaidou D, Toffalorio F, Bauer TM. Solomon BJ, et al. Among authors: shaw at. J Clin Oncol. 2024 May 31:JCO2400581. doi: 10.1200/JCO.24.00581. Online ahead of print. J Clin Oncol. 2024. PMID: 38819031

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,212 results

Search Page